Prometheus Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RXDX research report →
Range $67 – $200
Price Chart
About the company
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials.
- CEO
- Mark C. McKenna
- IPO
- 2021
- Employees
- 97
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on RXDX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.56B
- P/E
- -57.28
- PEG
- 2.75
- P/S
- 1403.81
- P/B
- 12.01
- EV/EBITDA
- -64.04
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -2140.96%
- Net Margin
- -2081.83%
- ROE
- -31.12%
- ROIC
- -20.21%
Latest fiscal year · YoY change
- Revenue
- $6.81M+117.6%
- Gross Profit
- $6.81M+117.6%
- Op Income
- $-145,778,000
- Net Income
- $-141,752,000-57.6%
- EPS
- $-3.49-21.6%
- OCF Growth
- -94.1%
- FCF Growth
- -94.9%
- 52W High
- $199.96
- 52W Low
- $23.27
- 50D MA
- $182.36
- 200D MA
- $108.85
- Beta
- -0.49
- RSI (14)
- 84
- Avg Volume
- 1.22M
No earnings-call transcripts are available for RXDX yet.
- Free Float
- 69.5%
- Shares Outstanding
- 47.81M
- Float Shares
- 33.23M
of shares held by institutions
242 13F filers
Buy/sell ratio 0.23. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dowling & Yahnke LLC | 29.61K | 0 |
| Crawford Lake Capital Management, LLC | 15.83K | ▲ 15.83K |
| Gyon Technologies Capital Management, LP | 3.29K | ▲ 3.29K |
| Harvest Group Wealth Management, LLC | 8 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 23 | Hendrix Martin | sell | 40,000 |
| Jun 16, 23 | Hendrix Martin | sell | 20,500 |
| Jun 16, 23 | Hendrix Martin | sell | 2,071 |
| Jun 16, 23 | Laur James | sell | 20,500 |
| Jun 16, 23 | Laur James | sell | 2,071 |
| Jun 16, 23 | Laur James | sell | 40,000 |
| Jun 16, 23 | Stenhouse Mark | sell | 34,085 |
| Jun 16, 23 | Stenhouse Mark | sell | 40,000 |
| Jun 16, 23 | Stenhouse Mark | sell | 70,371 |
| Jun 16, 23 | Stenhouse Mark | sell | 240,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RXDX coverage
Recent articles, reports, and earnings notes.
No research on RXDX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RXDX report →Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
cnbc.com · Aug 1
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, MDWT, RUTH
headlinesoftoday.com · May 22
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
businesswire.com · May 22
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?
zacks.com · May 12
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
zacks.com · May 9
PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
businesswire.com · Apr 21
Why Prometheus Biosciences Stock Is Skyrocketing This Week
fool.com · Apr 20
Why Merck Is Buying Prometheus Biosciences For About $10.8 Billion
pulse2.com · Apr 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.